Clinical Pharmacokinetics

, Volume 32, Issue 6, pp 481–495 | Cite as

Cyclosporin Pharmacokinetics in Paediatric Transplant Recipients

Review Article Special Populations


Cyclosporin is an essential component of the antirejection drug protocol used in the long term management of paediatric organ transplant recipients. This article looks at the pharmacokinetics of cyclosporin in paediatric kidney, heart, liver and bone marrow transplant recipients and critically evaluates its relationship to pharmacokinetic data in adult transplant recipients.

There are limited data on the pharmacokinetics of cyclosporin in paediatric transplant recipients (14 publications provide the database) as compared with the adult transplant population. Study design, analytical methodology and age ranges of the individuals differ between studies, making comparative interpretation of pharmacokinetic data difficult. However, significant trends are noteworthy and these may influence dose administration guidelines and therapeutic monitoring standards for cyclosporin in the paediatric organ transplant recipient.

The bioavailability of the oral formulations of cyclosporin is highly variable as with the adult population, but there appears to be a correlation between cyclosporin bioavailability and age with both the traditional oral formulation (Sandimmun®) and the new microemulsion formulation (Neoral®) in young liver transplant patients. Bowel length, presystemic metabolism in the gut wall, type of transplant and time since transplant are contributing factors in the variation of bioavailability patterns in paediatric transplant patients.

The volume of distribution of cyclosporin does not appear to differ between paediatric and adult transplant recipients, but systemic clearance is comparatively higher in the paediatric population. In general, paediatric patients require higher doses of cyclosporin to achieve target blood concentrations of the drug which are equivalent to the values used in the adult population. Younger patients (less than 8 years of age) may be managed more effectively with a 3 times daily administration schedule rather than the twice daily schedule which is universally used for cyclosporin in the transplant population.

The comparatively higher doses and more frequent administration schedule used in paediatric transplant recipients are the consequence of age-related differences in bioavailability and the possibility of increased metabolic clearance of the drug in younger patients.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fine RN. Renal transplantation of the infant and young child and the use of paediatric cadaver kidneys for transplantation in paediatric and adult recipients. Am J Kidney Dis 1988; 12: 1–10PubMedGoogle Scholar
  2. 2.
    Addonizio LJ. Cardiac transplantation in the paediatric patient. Prog Cardiovasc Dis 1990; 33: 19–34PubMedCrossRefGoogle Scholar
  3. 3.
    Paradis KJG, Freese DK, Sharp HL. A paediatric perspective on liver transplantation. Pediatr Clin North Am 1988; 35: 409–33PubMedGoogle Scholar
  4. 4.
    Kahn D, Esquivel CO, Makowka L, et al. Causes of death after liver transplantation in children treated with cyclosporine And steroids. Clin Transplant 1989; 3: 150–5Google Scholar
  5. 5.
    Michler RE, Fox IJ, Hardy MA. Paediatric organ transplantation: History, current status and important trends. Sandoz Transplantation Series Monograph — 1992. East Hanover (NJ): Sandoz Pharmaceuticals Corp., 1992Google Scholar
  6. 6.
    Ettenger RB, Rosenthal JT, Mark J, et al. Long term results with cyclosporine immune suppression iin pediatric codaver renal transplantation. Transplant Proc 1991 Feb; 23: 1011–2PubMedGoogle Scholar
  7. 7.
    Laine J, Hoppu K, Holmberg C. Renal allograft function and histology in children on triple immunosupression based on individual pharmacokinetically determined cyclosporine administration. Transplant Proc 1994; 26(5): 2775–6PubMedGoogle Scholar
  8. 8.
    Najarian JS, Frey DJ, Matas AJ, et al. Renal transplantation in infants. Ann Surg 1990; 212: 353–67PubMedCrossRefGoogle Scholar
  9. 9.
    UNOS. Paediatric graft and survival data released. UNOS Update 1991; 7: 5Google Scholar
  10. 10.
    Belle SH, Detre KM, Beringer KC, et al. Liver transplantation in the United States. In: Terasaki PI, editor. Clinical transplants: 1990. Los Angeles: UCLA Tissue Typing Laboratory, 1991: 11–9Google Scholar
  11. 11.
    Kriett JM, Kaye MR The registry of the International Society for Heart and Lung Transplantation: eighth official report - 1991. J Heart Lung Transplant 1991; 10: 491–8PubMedGoogle Scholar
  12. 12.
    Broyer M, Gagnadoux MF, Guest G, et al. Triple therapy including cyclosporine A verses conventional regimen: a randomized prospective study in paediatric kidney transplantation. Transplant Proc 1987; 19: 3582–5PubMedGoogle Scholar
  13. 13.
    MacDonell Jr RC, Johnson K, Ritchie R, et al. Paediatric renal transplantation results are improved with triple drug therapy with cyclosporine A, azathioprine, and prednisone. Transplant Proc 1989; 21: 1701–4PubMedGoogle Scholar
  14. 14.
    Klare B, Strom TM, Hahn H, et al. Remarkable long-term prognosis and excellent growth in kidney-transplant children under cyclosporine A monotherapy. Transplant Proc 1991; 23: 1013–7PubMedGoogle Scholar
  15. 15.
    Margarit C, Martinez-Ibanez V, Tormo R, et al. Maintainence immunosuppression without steroids in paediatric liver transplantion. Transplant Proc 1989; 21: 2230–1PubMedGoogle Scholar
  16. 16.
    Hodson EM, Knight JF, Sheil AGR, et al. Cyclosporine A as sole immunosuppressive agent for renal transplantation in children: effect of catch-up growth. Transplant Proc 1989; 21: 1687–92PubMedGoogle Scholar
  17. 17.
    Reisman L, Lieberman KV, Burrows L, et al. Follow-up of cyclosporine A-treated paediatric renal allograft recipients after cessation of prednisone. Transplantation 1990; 49: 76–80PubMedCrossRefGoogle Scholar
  18. 18.
    Hilbrands LB, Hoitsma AJ, Koene KA. Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation. Transplantation 1996; 61(7): 1038–46PubMedCrossRefGoogle Scholar
  19. 19.
    Hoyer PF, Krohn HP, Offner G, et al. Renal function after kidney transplantation in children. Transplantation 1987; 43: 489–93PubMedCrossRefGoogle Scholar
  20. 20.
    Berg UB, Bohlin A-B. Renal transplantation in children: renal function follow-up of cyclosporine A-treated children. Transplant Proc 1990; 22: 160–1PubMedGoogle Scholar
  21. 21.
    Andrews WA, Arant BS, Fyock B, et al. The effect of cyclosporine A on long-term renal function in paediatric liver transplant recipients. Transplant Proc 1991; 23: 1452–3PubMedGoogle Scholar
  22. 22.
    Sommerauer JF, Howard J, Grant D. Renal function following liver transplantation in children. Transplant Proc 1991; 23: 1466–8PubMedGoogle Scholar
  23. 23.
    Lawless S, Ellis D, Thompson A, et al. Mechanisms of hypertension during and after orthoptic liver transplantation in children. J Pediatr 1989; 115: 372–9PubMedCrossRefGoogle Scholar
  24. 24.
    Jaffe SJ, Aranda JV, editors. Paediatric pharmacology. Therapeutic principles in practice. 2nd ed. Philadelphia: WB Saunders, 1992Google Scholar
  25. 25.
    Radde IC, MacLeod SM, editors. Paediatric pharmacology and therapeutics. 2nd ed. St Louis: Mosby Press, 1993: 57–86Google Scholar
  26. 26.
    Ohlman S, Lindholm A, Hagglund H, et al. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur J Clin Pharmacol 1993; 44: 265–9PubMedCrossRefGoogle Scholar
  27. 27.
    Motil KJ. Development of the gastrointestinal tract. In: Wyllie R, Hyams JS, editor. Paediatric gastrointestinal disease. Philadelphia: WB Saunders Co., 1993: 3–15Google Scholar
  28. 28.
    Venkataramanan R, Habucky K, Burckart GJ, et al. Clinical pharmacokinetics in organ transplant patients. Clin Pharmacokinet 1989; 16: 134–61PubMedCrossRefGoogle Scholar
  29. 29.
    Whitington P, Emond J, Whitington S, et al. Small-bowel length and the dose of Cyclosporine A in children after liver transplantation. N Engl J Med 1990; 322: 733–8PubMedCrossRefGoogle Scholar
  30. 30.
    Winsberg B, Perel J, HurWic M, et al. Imipramine protein binding and pharmacokinetics in children. In: Forrest I, Carr C, Usdin E, editors. The phenothiazines and structurally related drugs. New York: Raven Press, 1974: 425–31Google Scholar
  31. 31.
    Morselli PL, Franco-Morselli R, Bossi R. Clinical pharmacokinetics in newborns and infants: age-related differences and therapeutic implications. Clin Pharmacokinet 1980; 5: 485–527PubMedCrossRefGoogle Scholar
  32. 32.
    Klotz U. Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications. Clin Pharmacokinet 1976; 1: 204–18PubMedCrossRefGoogle Scholar
  33. 33.
    Appel GB. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169–83PubMedCrossRefGoogle Scholar
  34. 34.
    Hamberger C, Urien S, Barre J, et al. Distribution of Cyclosporine A between blood cells and plasma of cardiac and renal transplant recipients. Ther Drug Monit 1988; 10: 28–33PubMedGoogle Scholar
  35. 35.
    Antikainen M, Holmberg C. Short-term effects of renal transplantation on plasma lipids and lipoprotein lipase in children with congenital nephrosis. Clin Nephrol 1994; 41: 284–9PubMedGoogle Scholar
  36. 36.
    Becker DM, Chamberlain B, Schwank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988; 85: 632–8PubMedCrossRefGoogle Scholar
  37. 37.
    Awni WM, Heim-Duthoy K, Kasiske BL. Impact of lipoproteins on cyclosporine pharmacokinetics and biological activity in transplant recipients. Transplant Proc 1990; 22: 1193–6PubMedGoogle Scholar
  38. 38.
    Natha DG, Oski FA, editors. Hematology in infancy and childhood. Philadelphia: WB Saunders Co., 1987: 266Google Scholar
  39. 39.
    Zaghloul I, Ptachicinski RJ, Burckart GJ, et al. Blood protein binding of Cyclosporine A in transplant patients. J Clin Pharm 1987; 27: 240–2Google Scholar
  40. 40.
    Radde IC, Kalow W. Drug biotransformation and its development. In: Radde IC, MacLeod SM, editors. Paediatric pharmacology and therapeutics. 2nd ed. St Louis: Mosby Press, 1993: 57–86Google Scholar
  41. 41.
    Harmon WE, Sullivan EK. Cyclosporine A dosing and its relationship to outcome in paediatric renal transplantation. Kidney Int 1993; 44 Suppl. 43: 550–5Google Scholar
  42. 42.
    Bleyer W. Antineoplastic agents. In: Jaffe SJ, editor. Paediatric pharmacology: therapeutic principles in practice. 1st ed. New York: Grune & Stratton, 1980: 349–77Google Scholar
  43. 43.
    Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30(5): 329–32PubMedCrossRefGoogle Scholar
  44. 44.
    Cooney GF, Dunn SP, Kaiser B, et al. Oral Cyclosporine A pharmacokinetics in paediatric renal and liver transplant recipients. Transplant Proc 1994; 26(5): 2779–80PubMedGoogle Scholar
  45. 45.
    Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporine A. Clin Pharmacokinet 1986a; 11: 107–32PubMedCrossRefGoogle Scholar
  46. 46.
    Frey FJ, Horber FF, Frey BM. Trough level and concentration time curves of Cyclosporine A in patients undergoing renal transplantation. Clin Pharmacol Ther 1988; 43: 55–62PubMedCrossRefGoogle Scholar
  47. 47.
    Ptachcinski R, Burckart G, Rosenthal J, et al. Cyclosporine A pharmacokinetics in children following cadaveric renal transplantation. Transplant Proc 1986; 18(4): 766–7Google Scholar
  48. 48.
    Neiberger R, Weiss R, Gomez M, et al. Elimination kinetics of Cyclosporine A following oral administration to children with renal transplants. Transplant Proc 1987; 19: 1525PubMedGoogle Scholar
  49. 49.
    Bauma WD, Veremis SA, Maddux MS, et al. Optimizing Cyclosporine A use in paediatric patients by measuring pretransplant blood levels. Transplant Proc 1987; 19(1): 1709–10PubMedGoogle Scholar
  50. 50.
    Humbert H, Guest G, Said MB, et al. Steady state pharmacokinetics of cyclosporine in renal; transplant patients: does an influence of age or body weight exist? Transplant Proc 1994; 26: 2791–7PubMedGoogle Scholar
  51. 51.
    Jacqz-Aigrain E, MontSs C, Brun P, Loirat C. Cyclosporine A pharmacokinetics in nephrotic and kidney transplant paediatric patients. Eur J Clin Pharmacol 1994; 47: 61–5PubMedGoogle Scholar
  52. 52.
    Venkataramanan R, Burckart G, Ptachcinski R, et al. Cyclosporine A pharmacokinetics in heart transplant patients. Transplant Proc 1986; 18(4): 768–70Google Scholar
  53. 53.
    Burckart G, Venkataramanan R, Fricker F, et al. Cyclosporine A kinetics in paediatric patients with congestive heart failure. Transplant Proc 1987; 19(1): 1528–29PubMedGoogle Scholar
  54. 54.
    Burckart G, Starzl T, Williams L, et al. Cyclosporine A monitoring and pharmacokinetics in paediatric liver transplant patients. Transplant Proc 1985; 17(1): 1172–5PubMedGoogle Scholar
  55. 55.
    Burckart G, Venkataramanan R, Ptachcinski R, et al. Cyclosporine absorption following orthotopic liver transplantation. J Clin Pharmacol 1986; 26: 647–51PubMedGoogle Scholar
  56. 56.
    Sokol RJ, Johnson KE, Karrer FM, et al. Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E. Lancet 1991; 338(8761): 212–214PubMedCrossRefGoogle Scholar
  57. 57.
    Dunn SP, Cooney GF, Kulinsky A, et al. Absorption characteristics of a microemulsion formulatiion of cyclosporine A in de novo paediatric liver transplant recipients. Transplantation 1995; 60(12): 1438–42PubMedCrossRefGoogle Scholar
  58. 58.
    Yee G, Lennon T, Gmur D, et al. Age-dependent Cyclosporine A: pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 1986; 40(4): 438–43PubMedCrossRefGoogle Scholar
  59. 59.
    Yee G, McGuire T, Gmur D, et al. Blood Cyclosporine A pharmacokinetics in patients undergoing marrow transplantation. Transplantation 1988; 46(3): 399–402PubMedCrossRefGoogle Scholar
  60. 60.
    Ptachcinski RJ, Venkataramanan R, Rosenthal JT, et al. Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther 1985; 38: 296–300PubMedCrossRefGoogle Scholar
  61. 61.
    Heifets M, Cooney GF, Shaw LM, et al. Diurnal variation of cyclosporine A clearance in stable renal transplant recipients receiving continuous infusion. Transplantation 1995; 60(12): 1615–7PubMedGoogle Scholar
  62. 62.
    Hoppu K, Koskimies O, Holmberg C, et al. Pharmacokinetically determined Cyclosporine A dosage in young children. Pediatr Nephrol 1991; 5: 1–4PubMedCrossRefGoogle Scholar
  63. 63.
    Lin CY, Lee SF. Comparison of pharmacokinetics between CsA capsules and Sandimmun Neoral in paediatric patients. Transplant Proc 1994; 26(5): 2973–4PubMedGoogle Scholar
  64. 64.
    Bokenkamp A, Offner G, Hoyer PF, et al. Improved absorption of cyclosporin A from a new microemulsion formulation: implications for dosage and monitoring. Paediatr Nephrol 1995; 9(2): 196–8CrossRefGoogle Scholar
  65. 65.
    Ettenger RE, Smith HT, Cooney GF, et al. Use of Neural in pediatric renal transplantation. Transplant Proc 1996; 28(4): 2257–8PubMedGoogle Scholar
  66. 66.
    Alberti D, Wallemacq P, Falchetti D, et al. Microemulsion formulation of cyclosporine in paediatric liver transplantation. Transplantation 1996; 61(3): 512–4PubMedCrossRefGoogle Scholar
  67. 67.
    Hoppu K, Jalanko H, Laine J, et al. Comparison of conventional oral cyclosporine and cyclosporine microemulsion formulations in children with a liver transplant. Transplantation 1996; 62: 1–6CrossRefGoogle Scholar
  68. 68.
    Dunn SP, Cooney GF, Sommerauer J, et al. Enhanced bioavailability of Neoral compared to Sandimmune in paediatric stable liver transplant patients. Transplantation 1997. In pressGoogle Scholar
  69. 69.
    Mehta MU, Venkataramanan R, Burckart GJ, et al. Effect of bile in cyclosporine absorption in transplant patients. Br J Clin Pharm 1988; 25: 579–84CrossRefGoogle Scholar
  70. 70.
    Kehrer BH, Whitington PF, Black DD. The effect of Roux-en-Y biliary enterostomy on the absorption of Cyclosporine A: relevance to poor drug bioavailability in children after orthotopic liver transplantation. Transplant Proc 1988; 20(2): 523–8PubMedGoogle Scholar
  71. 71.
    Tjia JF, Webber IR, Back DJ. Cyclosporin Metabolism by the Gastrointestinal Mucosa. Br J Clin Pharmacol 1991; 31(3): 344–6PubMedCrossRefGoogle Scholar
  72. 72.
    Webber IR, Peters WH, Back DJ. Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br J Clin Pharmacol 1992; 33(6): 661–4PubMedCrossRefGoogle Scholar
  73. 73.
    Mancel-Grosso V, Bertault-Peres P, Barthelemy A, et al. Pharmacokinetics of Cyclosporine A in bilateral lung transplantation candidates with cystic fibrosis. Transplant Proc 1990; 22(4): 1706–7PubMedGoogle Scholar
  74. 74.
    Awni WM, Sawchuk RJ. The pharmacokinetics of cyclosporine A II: blood plasma distribution and binding studies. Drug Metab Dispos 1985; 13(2): 133–8PubMedGoogle Scholar
  75. 75.
    Newberger J, Kahan BD. Cyclosporine A pharmacokinetics in man. Transplant Proc 1983; 15: 2413–5Google Scholar
  76. 76.
    Jain AB, Fung JJ, Tzakis AG, et al. Comparative study of Sandimmune and FK 506 dosage requirements in adult and paediatric orthotopic liver transplant patients. Transplant Proc 1991; 23(6): 2763–6PubMedGoogle Scholar
  77. 77.
    Hoppu K, Koskimies O, Holmberg C, et al. Evidence for prehepatic metabolism of oral Cyclosporine A in children. Br J Clin Pharmacol 1991; 32: 477–81PubMedCrossRefGoogle Scholar
  78. 78.
    Paradis K, Al Edreesi M, St-Vil D, et al. Cyclosporine kinetics in paediatric liver transplant recipients: impact of dose fractionation on true glomerular filtration rate. Transplant Proc 1994; 26(5): 2777–8PubMedGoogle Scholar
  79. 79.
    Laine J, Krogerus L, Fyhrquist F, et al. Renal function and histopathologic changes in children after liver transplantation. J Paediatr 1994; 125(6): 863–9CrossRefGoogle Scholar
  80. 80.
    Cooney GF, Lum BL, Meligeni JA, et al. Pharmacokinetics of a microemulsion formulation of cyclosporine in paediatric liver transplant recipients. Transplant Proc 1996; 28: 2270–72PubMedGoogle Scholar
  81. 81.
    Masri MA, Dhawan VS, Hayes K, et al. Cyclosporine dosage according to pharmacokinetic profiles leads to better graft and patient survival rates and a decrease in cyclosporine consumption. Transplant Proc 1992; 24(5): 1718–20PubMedGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  1. 1.School of PharmacyTemple UniversityPhiladelphiaUSA
  2. 2.Department of Drug SafetySandoz Research InstituteEast HanoverUSA
  3. 3.Children’s HospitalUniversity of HelsinkiHelsinkiFinland

Personalised recommendations